These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 36859833)

  • 21. Role of p38alpha MAPK in cardiac apoptosis and remodeling after myocardial infarction.
    Ren J; Zhang S; Kovacs A; Wang Y; Muslin AJ
    J Mol Cell Cardiol; 2005 Apr; 38(4):617-23. PubMed ID: 15808838
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Erythropoietin enhances neovascularization of ischemic myocardium and improves left ventricular dysfunction after myocardial infarction in dogs.
    Hirata A; Minamino T; Asanuma H; Fujita M; Wakeno M; Myoishi M; Tsukamoto O; Okada K; Koyama H; Komamura K; Takashima S; Shinozaki Y; Mori H; Shiraga M; Kitakaze M; Hori M
    J Am Coll Cardiol; 2006 Jul; 48(1):176-84. PubMed ID: 16814664
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Erythropoietin responsive cardiomyogenic cells contribute to heart repair post myocardial infarction.
    Zafiriou MP; Noack C; Unsöld B; Didie M; Pavlova E; Fischer HJ; Reichardt HM; Bergmann MW; El-Armouche A; Zimmermann WH; Zelarayan LC
    Stem Cells; 2014 Sep; 32(9):2480-91. PubMed ID: 24806289
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Recombinant human erythropoietin protects the myocardium from ischemia-reperfusion injury and promotes beneficial remodeling.
    Calvillo L; Latini R; Kajstura J; Leri A; Anversa P; Ghezzi P; Salio M; Cerami A; Brines M
    Proc Natl Acad Sci U S A; 2003 Apr; 100(8):4802-6. PubMed ID: 12663857
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Erythropoietin improves the efficiency of endothelial progenitor cell therapy after myocardial infarction in mice: effects on transplanted cell survival and autologous endothelial progenitor cell mobilization.
    Cheng Y; Hu R; Lv L; Ling L; Jiang S
    J Surg Res; 2012 Jul; 176(1):e47-55. PubMed ID: 22595018
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A nonerythropoietic derivative of erythropoietin protects the myocardium from ischemia-reperfusion injury.
    Fiordaliso F; Chimenti S; Staszewsky L; Bai A; Carlo E; Cuccovillo I; Doni M; Mengozzi M; Tonelli R; Ghezzi P; Coleman T; Brines M; Cerami A; Latini R
    Proc Natl Acad Sci U S A; 2005 Feb; 102(6):2046-51. PubMed ID: 15671158
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Sca-1+ cardiac progenitor cell therapy with cells overexpressing integrin-linked kinase improves cardiac function after myocardial infarction.
    Ling L; Bai J; Gu R; Jiang C; Li R; Kang L; Ferro A; Xu B
    Transplantation; 2013 May; 95(10):1187-96. PubMed ID: 23598943
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Sphingosine-1-Phosphate Receptor Agonist Fingolimod Increases Myocardial Salvage and Decreases Adverse Postinfarction Left Ventricular Remodeling in a Porcine Model of Ischemia/Reperfusion.
    Santos-Gallego CG; Vahl TP; Goliasch G; Picatoste B; Arias T; Ishikawa K; Njerve IU; Sanz J; Narula J; Sengupta PP; Hajjar RJ; Fuster V; Badimon JJ
    Circulation; 2016 Mar; 133(10):954-66. PubMed ID: 26826180
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Clinical aspects of left ventricular diastolic function assessed by Doppler echocardiography following acute myocardial infarction.
    Poulsen SH
    Dan Med Bull; 2001 Nov; 48(4):199-210. PubMed ID: 11767125
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effect of erythropoietin as an adjunct to primary percutaneous coronary intervention: a randomised controlled clinical trial.
    Ludman AJ; Yellon DM; Hasleton J; Ariti C; Babu GG; Boston-Griffiths E; Venugopal V; Walker M; Holdright D; Swanton H; Crake T; Brull D; Moon JC; Puranik R; Muthurangu V; Taylor A; Hausenloy DJ
    Heart; 2011 Oct; 97(19):1560-5. PubMed ID: 21900585
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Migration of bone marrow-derived cells and improved perfusion after treatment with erythropoietin in a murine model of myocardial infarction.
    Brunner S; Huber BC; Weinberger T; Vallaster M; Wollenweber T; Gerbitz A; Hacker M; Franz WM
    J Cell Mol Med; 2012 Jan; 16(1):152-9. PubMed ID: 21362129
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Repeated low-dose of erythropoietin is associated with improved left ventricular function in rat acute myocardial infarction model.
    Ben-Dor I; Hardy B; Fuchs S; Kaganovsky E; Kadmon E; Sagie A; Coleman R; Mansur M; Politi B; Fraser A; Harell D; Okon E; Battler A; Haim M
    Cardiovasc Drugs Ther; 2007 Oct; 21(5):339-46. PubMed ID: 17912622
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Coupling erythropoietin secretion to mesenchymal stromal cells enhances their regenerative properties.
    Copland IB; Jolicoeur EM; Gillis MA; Cuerquis J; Eliopoulos N; Annabi B; Calderone A; Tanguay JF; Ducharme A; Galipeau J
    Cardiovasc Res; 2008 Aug; 79(3):405-15. PubMed ID: 18397963
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Erythropoietin improves cardiac function through endothelial progenitor cell and vascular endothelial growth factor mediated neovascularization.
    Westenbrink BD; Lipsic E; van der Meer P; van der Harst P; Oeseburg H; Du Marchie Sarvaas GJ; Koster J; Voors AA; van Veldhuisen DJ; van Gilst WH; Schoemaker RG
    Eur Heart J; 2007 Aug; 28(16):2018-27. PubMed ID: 17576662
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Expandable human cardiovascular progenitors from stem cells for regenerating mouse heart after myocardial infarction.
    Schwach V; Gomes Fernandes M; Maas S; Gerhardt S; Tsonaka R; van der Weerd L; Passier R; Mummery CL; Birket MJ; Salvatori DCF
    Cardiovasc Res; 2020 Mar; 116(3):545-553. PubMed ID: 31287499
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Bone-derived Nestin-positive mesenchymal stem cells improve cardiac function via recruiting cardiac endothelial cells after myocardial infarction.
    Lu D; Liao Y; Zhu SH; Chen QC; Xie DM; Liao JJ; Feng X; Jiang MH; He W
    Stem Cell Res Ther; 2019 Apr; 10(1):127. PubMed ID: 31029167
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Single high-dose intramyocardial administration of erythropoietin promotes early intracardiac proliferation, proves safety and restores cardiac performance after myocardial infarction in rats.
    Gäbel R; Klopsch C; Furlani D; Yerebakan C; Li W; Ugurlucan M; Ma N; Steinhoff G
    Interact Cardiovasc Thorac Surg; 2009 Jul; 9(1):20-5; discussion 25. PubMed ID: 19380336
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cytokine combination therapy with erythropoietin and granulocyte colony stimulating factor in a porcine model of acute myocardial infarction.
    Angeli FS; Amabile N; Shapiro M; Mirsky R; Bartlett L; Zhang Y; Virmani R; Chatterjee K; Boyle A; Grossman W; Yeghiazarians Y
    Cardiovasc Drugs Ther; 2010 Dec; 24(5-6):409-20. PubMed ID: 20809214
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A small nonerythropoietic helix B surface peptide based upon erythropoietin structure is cardioprotective against ischemic myocardial damage.
    Ahmet I; Tae HJ; Juhaszova M; Riordon DR; Boheler KR; Sollott SJ; Brines M; Cerami A; Lakatta EG; Talan MI
    Mol Med; 2011; 17(3-4):194-200. PubMed ID: 21170473
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Transplantation of expanded bone marrow-derived very small embryonic-like stem cells (VSEL-SCs) improves left ventricular function and remodelling after myocardial infarction.
    Zuba-Surma EK; Guo Y; Taher H; Sanganalmath SK; Hunt G; Vincent RJ; Kucia M; Abdel-Latif A; Tang XL; Ratajczak MZ; Dawn B; Bolli R
    J Cell Mol Med; 2011 Jun; 15(6):1319-28. PubMed ID: 20629987
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.